Focused Wealth Management’s Provectus Biopharmaceuticals PVCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
– Sell
-9,250
Closed -$1K – 770
2018
Q1
$1K Hold
9,250
– – ﹤0.01% 682
2017
Q4
$1K Buy
+9,250
New +$1K ﹤0.01% 667
2017
Q3
– Sell
-12,205
Closed – – 773
2017
Q2
$0 Hold
12,205
– – ﹤0.01% 770
2017
Q1
$1K Buy
12,205
+9,250
+313% +$758 ﹤0.01% 676
2016
Q4
$0 Hold
2,955
– – ﹤0.01% 765
2016
Q3
$0 Hold
2,955
– – ﹤0.01% 729
2016
Q2
$1K Hold
2,955
– – ﹤0.01% 653
2016
Q1
$1K Hold
2,955
– – ﹤0.01% 636
2015
Q4
$1K Hold
2,955
– – ﹤0.01% 663
2015
Q3
$2K Hold
2,955
– – ﹤0.01% 614
2015
Q2
$2K Buy
2,955
+750
+34% +$612 ﹤0.01% 598
2015
Q1
$2K Buy
2,205
+500
+29% +$412 ﹤0.01% 617
2014
Q4
$1K Buy
+1,705
New +$1.56K ﹤0.01% 644

Other funds holding PVCT

Focused Wealth Management's PVCT Position: Q2 2018 in Review

Focused Wealth Management sold out of Provectus Biopharmaceuticals (PVCT) in Q2 2018, closing a stake of 9,250 shares — an estimated $1K sold.

Focused Wealth Management first reported a position in PVCT in Q4 2014 and held it in 13 quarters. The position peaked at $2K in Q3 2015. 3 funds tracked by Wall St. Rank hold PVCT as of Q2 2018.

  • Focused Wealth Management reported no remaining Provectus Biopharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Focused Wealth Management sold 9,250 Provectus Biopharmaceuticals shares in Q2 2018, an estimated $1K.
  • Focused Wealth Management first reported a position in Provectus Biopharmaceuticals in Q4 2014 and held it in 13 quarters.
  • Focused Wealth Management's Provectus Biopharmaceuticals position peaked at $2K in Q3 2015.
  • 3 funds tracked by Wall St. Rank held Provectus Biopharmaceuticals as of Q2 2018.

Based on Focused Wealth Management's 13F filing for Q2 2018, filed 15 Aug 2018.